RxDoctor Payments Data

Himad Ullah Khattak, MD

Cardiovascular Disease · Middletown, OHNPI 1265691364

Payments from drug & device makers

$1,932in general payments, 2019–2025

Across 36 payments — averaging $53.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$537
  • Abbott$237
  • Abiomed$185
  • E.r. Squibb & Sons, L.L.C.$156
  • Janssen Scientific Affairs, LLC$125
  • Penumbra, Inc.$120
  • plus $572 from 10 others

What the payments were for

  • Food & beverage$1,92099%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,932 in reported general payments places this provider in the 50th percentile of 827 cardiovascular disease providers in Ohio.

See all cardiovascular disease providers in Ohio

Medicare billing

Part B allowed, 2024
$177,152
Medicare patients
527
Services billed
1,792

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol77$75,968
EliquisApixaban65$74,413
EntrestoSacubitril/Valsartan29$22,503
JardianceEmpagliflozin13$19,302
Ranolazine ErRanolazine80$7,065
Atorvastatin Calcium176$1,759
Metoprolol Succinate122$1,571
Pyridostigmine Bromide13$1,062
ClopidogrelClopidogrel Bisulfate116$1,031
FenofibrateFenofibrate Nanocrystallized29$917
Lisinopril125$866
Midodrine Hcl20$688
Isosorbide Mononitrate ErIsosorbide Mononitrate93$683
Furosemide247$631
Metoprolol Tartrate148$592

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$78$74,41365 claims
NovartisEntresto$537$22,50329 claims
Boehringer IngelheimJardiance$41$19,30213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 827 cardiovascular disease providers in Ohio.

Other cardiovascular disease in Middletown

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →